Hepatic NAD(+) deficiency as a therapeutic target for non-alcoholic fatty liver disease in ageing.

ABSTRACT:

Background and purpose

Ageing is an important risk factor of non-alcoholic fatty liver disease (NAFLD). Here, we investigated whether the deficiency of nicotinamide adenine dinucleotide (NAD(+) ), a ubiquitous coenzyme, links ageing with NAFLD.

Experimental approach

Hepatic concentrations of NAD(+) , protein levels of nicotinamide phosphoribosyltransferase (NAMPT) and several other critical enzymes regulating NAD(+) biosynthesis, were compared in middle-aged and aged mice or patients. The influences of NAD(+) decline on the steatosis and steatohepatitis were evaluated in wild-type and H247A dominant-negative, enzymically-inactive NAMPT transgenic mice (DN-NAMPT) given normal or high-fat diet (HFD).

Key results

Hepatic NAD(+) level decreased in aged mice and humans. NA

SUBMITTER: Zhou CC 

PROVIDER: S-EPMC4945761 | biostudies-literature | 2016 Aug

REPOSITORIES: biostudies-literature